MAPK3 and neoplasm: Apatinib, a novel small-molecule tyrosine kinase inhibitor, mainly highly selectively and powerfully inhibits the phosphorylation of VEGF-2 and the activation of downstream ERK-1/2-MAPK and PDK-AKT-mTOR pathways to block signaling and repress tumor neovascularization, thereby inhibiting tumor growth.